guselkumab

Ligand id: 7998

Name: guselkumab

No information available.
Summary of Clinical Use
Having completed Phase III clinical trials for various forms of psoriasis, guselkumab was FDA approved in July 2017 for patients with moderate to severe plaque psoriasis. Click here to link to ClinicalTrials.gov's listing of Phase III guselkumab trials.
Mechanism Of Action and Pharmacodynamic Effects
The cytokine IL23 plays an important role in modulating the immune system. Abberant expression of IL23 has been implicated in the pathogenesis of autoimmune diseases such as psoriasis [2] and arthritis [4]. Guselkumab neutralises circulating IL23 by binding the IL23A (p19) subunit, and thereby reduces pathological disease symptoms.